Promis Neurosciences Inc  

(Public, TSE:PMN)   Watch this stock  
Find more results for tse:amf
-0.0100 (-11.76%)
Oct 2 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.08 - 0.08
52 week 0.04 - 0.12
Open 0.08
Vol / Avg. 0.00/26,451.00
Mkt cap 11.43M
P/E     -
Div/yield     -
EPS -0.03
Shares 152.41M
Beta -0.53
Inst. own     -
Aug 13, 2015
Q2 2015 Promis Neurosciences Inc Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -33285.71% -
Operating margin -31785.71% -
EBITD margin - -
Return on average assets -479.05% -
Return on average equity - -
CDP Score - -


Suite 200, 1920 Yonge Street
+1-416-8476898 (Phone)
+1-416-8476899 (Fax)

Website links


Amorfix Life Sciences Ltd. (Amorfix) is a Canada-based product development company focused on therapeutic antibodies and diagnostics for the diagnosis and treatment of misfolded protein diseases, including amyotrophic lateral sclerosis (ALS), cancer and Alzheimer's disease (AD). Its technology includes the Epitope Protection technology, ProMIS and AMFIA. Amorfix's technology targets misfolded superoxide dismutase 1 (SOD1) through a passive infusion of manufactured monoclonal antibodies and an active immunization approach to elicit the production of similar antibodies by the patient's own immune system. The Company is engaged in the development of a blood test that measures misfolded SOD1 in blood, for the diagnosis of ALS. Amorfix has developed both a preclinical test for detection and measurement of aggregated Abeta, a recognized biomarker for AD, in animal models and a test for the detection of aggregated Abeta in human clinical samples.

Officers and directors

Eugene Williams Executive Chairman of the Board
Elliot Goldstein M.D. President, Chief Executive Officer, Director
Age: 64
Janet Clennett Director - Finance, Acting Chief Financial Officer
Neil Cashman M.D. Chief Scientific Officer, Director
Robert Gundel Ph.D. Director
Johannes Minho Roth Independent Director
Age: 36